| 3.2 0.15 (4.92%) | 11-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.93 | 1-year : | 4.59 |
| Resists | First : | 3.36 | Second : | 3.93 |
| Pivot price | 2.98 |
|||
| Supports | First : | 2.58 | Second : | 2.1 |
| MAs | MA(5) : | 3.06 |
MA(20) : | 2.91 |
| MA(100) : | 2.31 |
MA(250) : | 3.7  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83 |
D(3) : | 75.6 |
| RSI | RSI(14): 60.1 | |||
| 52-week | High : | 9.73 | Low : | 1.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RCOR ] has closed below upper band by 23.4%. Bollinger Bands are 46.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.2 - 3.22 | 3.22 - 3.24 |
| Low: | 2.96 - 2.98 | 2.98 - 3 |
| Close: | 3.17 - 3.2 | 3.2 - 3.23 |
Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.
Thu, 01 Dec 2022
Rocket Pharmaceuticals Completes Acquisition of Renovacor - Business Wire
Wed, 16 Nov 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCOR, SLDB, OFIX, IMRA - Digital Journal
Tue, 20 Sep 2022
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy - Business Wire
Tue, 12 Jul 2022
Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of ... - Business Wire
Wed, 01 Jun 2022
Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered ... - Business Wire
Thu, 02 Sep 2021
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 38.5 (%) |
| Held by Institutions | 57.5 (%) |
| Shares Short | 224 (K) |
| Shares Short P.Month | 215 (K) |
| EPS | -3.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.05 |
| PEG Ratio | 0 |
| Price to Book value | 1 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|